Benzinga | Dec 7, 2020 08:37AM EST

Roth Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $170

Roth Capital analyst Tony Butler maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $115 to $170.